Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Daishenning is a traditional Dai ethnic medicine developed by the Xishuangbanna Dai Autonomous Prefecture Dai Medical Hospital for the treatment of chronic kidney disease (CKD). Formulated based on the principles of Dai medicine, which focuses on the balance of the four elements (earth, water, fire, and wind), the drug is intended to improve renal function, reduce urinary protein levels, and manage symptoms of chronic renal failure. It is classified as a hospital-made preparation (院内制剂) in China, meaning it is produced and used primarily within the developing hospital's clinical setting under specific provincial regulatory approval. The formulation typically consists of a complex mixture of herbal extracts native to the Xishuangbanna region, designed to regulate the body's internal towers and channels to restore renal health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Daishenning.